http://www.sanford.com.au/sanford/Members/MarketInfo/News.asp?Source=RWE&ArticleID=247725
Proteome Systems reaches biomarkers milestone
09:10, Friday, 1 April 2005
Sydney - Friday - April 1: (RWE Australian Business News) -
Proteome Systems (ASX:PXL ) reports the achievement of a milestone under
a collaborative agreement with the US-based HighQ Foundation for the
discovery of biomarkers for monitoring the progression of Huntington's
disease (HD) and the effectiveness of treatments in clinical trials.
The milestone, involving proteomic analysis of diseased and
normal individuals, was reached four months into the 18-month agreement
and involved identification of the first candidate biomarkers for HD in
clinical samples of plasma and cerebrospinal fluid.
The milestone payment was US$300,000.
HD is an inherited disease that affects about 1 in 10,000 adults
in the Western world — usually between the ages of 30 and 50 years — and
is invariably fatal.
Huntington's disease is associated with neurodegeneration
leading to a progressive decline in physical movement and mental
processes.
There is currently no effective treatment.
ENDS
PXL
proteome systems limited
http://www.sanford.com.au/sanford/Members/MarketInfo/News.asp?Sou...
Add to My Watchlist
What is My Watchlist?